Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|February 7, 2023
7 Stories for February 7: Observing National Black HIV/AIDS Awareness Day
Author(s)Nina Cosdon
February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.
Advertisement
February 7 is National Black HIV/AIDS Awareness Day. First observed in 1999, National Black HIV/AIDS Awareness Day acknowledges how Black communities are disproportionately affected by
Contagion has compiled 10 articles, interviews, and podcasts to observe this day and to disseminate information about the state of HIV/AIDS in Black individuals.
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Advertisement
Advertisement
Trending on Contagion Live
1
A Pennsylvania Teen Dies From Rare Measles Neurological Complication
2
Revisiting Whether Cefepime Raises Mortality Risk
3
Ceftriaxone Safety: Separating Signal From Risk
4
New York City Orders Tower Cleanings, Announces Prevention Measures in Addressing Legionnaires' Disease Cluster
5